No evidence of an effect of the M184I/V on the doravirine/lamivudine/tenofovir switch efficacy in people with HIV

Among PWH with antiretroviral experience, there was no evidence that switching to doravirine + lamivudine plus tenofovir affected short-term treatment response in individuals harboring HIV M184I/V mutations.